Mini Test Dose of Intravenous Busulfan (Busulfex(®)) in Allogeneic Non-Myeloablative Stem Cell Transplantation, Followed by Liquid Chromatography Tandem-Mass Spectrometry

Ítems similars

• MYELOABLATIVE INTRAVENOUS BUSULFAN/FLUDARABINE CONDITIONING DOES NOT FACILITATE RELIABLE ENGRAFTMENT OF DUAL UMBILICAL CORD BLOOD GRAFTS IN ADULT RECIPIENTS
  per: Horwitz, Mitchell E., et al.
  Publicat: (2008)
• Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry
  per: Moon, Soo Young, et al.
  Publicat: (2014)
• Response and toxicity of donor lymphocyte infusions following T cell depleted non-myeloablative allogeneic hematopoietic stem cell transplantation from 3–6/6 HLA matched donors
  per: Rizzieri, David A, et al.
  Publicat: (2008)
• Fludarabine-based Non-myeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics
  per: Horwitz, Mitchell E., et al.
  Publicat: (2007)
• Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine
  per: Harris, Andrew C., et al.
  Publicat: (2018)